

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/129428 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/18 (2006.01)
C07K 16/42 (2006.01) C07K 16/30 (2006.01)
C07K 14/47 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/086331

(22) International Filing Date:

16 December 2021 (16.12.2021)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/126,356 16 December 2020 (16.12.2020) US
20216705.2 22 December 2020 (22.12.2020) EP
63/182,394 30 April 2021 (30.04.2021) US

(71) Applicant: **MOLECULAR PARTNERS AG** [CH/CH];
Wagistraße 14, 8952 Zürich-Schlieren (CH).

(72) Inventors: **GRIMM, Sebastian**; c/o Molecular Partners AG, Wagistraße 14, 8952 Zürich-Schlieren (CH). **RESCHKE, Nina**; c/o Molecular Partners AG, Wagistraße 14, 8952 Zürich-Schlieren (CH). **REICHEN, Christian**; c/o Molecular Partners AG, Wagistraße 14, 8952 Zürich-Schlieren (CH). **SCHLERETH, Bernd**; c/o Molecular Partners AG, Wagistraße 14, 8952 Zürich-Schlieren (CH). **LEVITSKY, Victor**; c/o Molecular Partners AG, Wagistrasse 14, 8952 Zürich-Schlieren (CH). **JEANBART, Laura**; c/o Molecular Partners AG, Wagistraße 14, 8952 Zürich-Schlieren (CH).

(74) Agent: **VOSSIUS & PARTNER (NO 31) PATENTANWÄLTE RECHTSANWÄLTE MBB**; Siebertstrasse 3, 81675 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: RECOMBINANT CD3 BINDING PROTEINS AND THEIR USE

(57) Abstract: The present invention relates to recombinant binding proteins comprising a designed ankyrin repeat domain with binding specificity for CD3. In addition, the invention relates to nucleic acids encoding such binding proteins, pharmaceutical compositions comprising such binding proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods of disease-localized activation of T cells, and in methods of treating diseases, such as infectious diseases or cancer, in a mammal, including a human.



WO 2022/129428 A1